Source BioScience PLC Expansion of online diagnostic testing service
02 Dezembro 2015 - 5:01AM
RNS Non-Regulatory
TIDMSBS
Source BioScience PLC
02 December 2015
2 December 2015
Source BioScience plc
("Source BioScience" or the "Group")
Source BioScience expands online diagnostic testing and launches
prescription service
Just Between Us(TM) sexual health service enhanced to include
home-sampling and secure online access to diagnostic testing for
HIV and hepatitis B and C
Source BioScience (LSE: SBS) the international laboratory
services and diagnostics business announces significant
enhancements to the Group's Just Between Us(TM) online sexually
transmitted infection ("STI") testing service with the launch of
five new home-sampling tests for STI's and an online prescription
service.
Just Between Us(TM) already enables access to home-sampling for
the diagnosis of Chlamydia and Gonorrhoea infection. The enhanced
sexual health service now also provides online access to:
-- home-sampling for HIV, syphilis, hepatitis B and C
-- STI screening for ten of the most commonly-occurring sexually transmitted infections
-- professional counselling, advice and support following a positive test result
-- online prescriptions and treatment for non-complex STI's
Dr Nick Ash, CEO said: "Just Between Us(TM) has been providing
online access to sexual health testing for over three years and
during this period more than 100,000 people have used the service
every year.
"The enhanced offering will enable individuals, who might find
it embarrassing or inconvenient to attend their GP or local sexual
health clinic, rapid access to a broader range of tests from the
privacy of their own home. A number of sexually transmitted
infections can present without symptoms and many individuals are
unaware that they have an infection; in the UK an estimated 24% of
people living with HIV are unaware of their infection.
"By providing a comprehensive sexual health service, including
home-sampling, accredited laboratory diagnostics, access to
counselling and support and an online prescription service, we hope
to contribute to the diagnosis, management and treatment of a
significant number of sexually transmitted infections."
--ENDS--
For further information, please contact:
Source BioScience plc
Dr Nick Ash, CEO
Tel: +44 (0) 115 973 9010
Email: enquiries@sourcebioscience.com
www.sourcebioscience.com
About Source BioScience
Source BioScience plc (LSE: SBS) is a trusted provider of state
of the art laboratory services and products to the healthcare and
clinical, life and applied sciences and biopharma industries. It is
an international business operating ten state of the art facilities
in five countries and with customers in over 90 countries
worldwide. The Group offers a complementary portfolio of laboratory
services and products that share common technologies, laboratory
processes, infrastructure and expertise. These include clinical
diagnostics, genomics, proteomics, drug discovery and development
research as well as controlled environment storage and testing
services for a diverse range of markets. These services and
products are provided to a large and diverse customer base
including the top 50 pharmaceutical companies, leading universities
and research institutes worldwide, the UK NHS and other healthcare
providers. The Group is listed on the Premium Main Market of the
London Stock Exchange
About Just Between Us(TM)
Just Between Us(TM) provides discreet postal laboratory sexual
health testing services from highly accredited, state of the art
facilities. Aiming to make sexual health screening accessible for
all, Just Between Us(TM) STI test kits are ordered online and
delivered to any address. In addition to testing services, Just
Between Us(TM) provides an online prescription service and works in
partnership with The Terrence Higgins Trust to provide further help
and support to those who test positive for HIV, syphilis, hepatitis
B or hepatitis C.
The full range of Just Between Us(TM) services can be accessed
at www.jbu-clinic.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFSIFWFFISELE
(END) Dow Jones Newswires
December 02, 2015 02:01 ET (07:01 GMT)
Medical Solutions (LSE:MLS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Medical Solutions (LSE:MLS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024